Literature DB >> 18508797

Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia.

Sofia Jönsson, Bob Olsson, Claes Ohlsson, Mattias Lorentzon, Dan Mellström, Hans Wadenvik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18508797     DOI： 10.3324/haematol.12373

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib.

Authors:  Hansjoerg Schmid; Bernadette A S Jaeger; Judith Lohse; Meinolf Suttorp
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

2.  Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia.

Authors:  Meinolf Suttorp; Christian Thiede; Josephine T Tauer; Ursula Range; Brigitte Schlegelberger; Nils von Neuhoff
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

3.  Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.

Authors:  Fiorina Giona; Stefania Mariani; Lucio Gnessi; Maria Luisa Moleti; Massimiliano Rea; Annalisa De Vellis; Deborah Marzella; Anna Maria Testi; Robin Foà
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

Review 4.  Endocrine side effects of broad-acting kinase inhibitors.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

5.  Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro.

Authors:  Sofia Jönsson; Henrik Hjorth-Hansen; Bob Olsson; Hans Wadenvik; Anders Sundan; Therese Standal
Journal:  J Bone Miner Metab       Date:  2011-10-14       Impact factor: 2.626

Review 6.  Clinical review: kinase inhibitors: adverse effects related to the endocrine system.

Authors:  Maya B Lodish
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

7.  Use of imatinib in the prevention of heterotopic ossification.

Authors:  Clément M L Werner; Stefan M Zimmermann; Carola C Würgler-Hauri; Joseph M Lane; Guido A Wanner; Hans-Peter Simmen
Journal:  HSS J       Date:  2013-06-21

8.  The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.

Authors:  Hichame Id Boufker; Laurence Lagneaux; Mehdi Najar; Martine Piccart; Ghanem Ghanem; Jean-Jacques Body; Fabrice Journé
Journal:  BMC Cancer       Date:  2010-06-17       Impact factor: 4.430

9.  SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation.

Authors:  Cesarina Giallongo; Piera La Cava; Daniele Tibullo; Ignazio Barbagallo; Nunziatina Parrinello; Alessandra Cupri; Fabio Stagno; Carla Consoli; Annalisa Chiarenza; Giuseppe A Palumbo; Francesco Di Raimondo
Journal:  BMC Cancer       Date:  2013-02-05       Impact factor: 4.430

10.  Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment.

Authors:  Bernadette Anna Sophia Jaeger; Josephine Tabea Tauer; Anna Ulmer; Eberhard Kuhlisch; Heinz Juergen Roth; Meinolf Suttorp
Journal:  Med Sci Monit       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.